These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 15736514)
1. Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Shepherd J; Brodin HF; Cave CB; Waugh NR; Price A; Gabbay J Int J Technol Assess Health Care; 2005; 21(1):47-54. PubMed ID: 15736514 [TBL] [Abstract][Full Text] [Related]
2. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877 [TBL] [Abstract][Full Text] [Related]
3. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Hartwell D; Jones J; Baxter L; Shepherd J Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834 [TBL] [Abstract][Full Text] [Related]
4. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Shepherd J; Jones J; Takeda A; Davidson P; Price A Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047 [TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. Sullivan SD; Craxi A; Alberti A; Giuliani G; De Carli C; Wintfeld N; Patel KK; Green J Pharmacoeconomics; 2004; 22(4):257-65. PubMed ID: 14974875 [TBL] [Abstract][Full Text] [Related]
6. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Wright M; Grieve R; Roberts J; Main J; Thomas HC; Health Technol Assess; 2006 Jul; 10(21):1-113, iii. PubMed ID: 16750059 [TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6. Kapol N; Lochid-Amnuay S; Teerawattananon Y BMC Gastroenterol; 2016 Aug; 16(1):91. PubMed ID: 27492396 [TBL] [Abstract][Full Text] [Related]
8. Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain. Turnes J; Romero-Gómez M; Planas R; Solà R; García-Samaniego J; Diago M; Crespo J; Calleja JL; Rubio-Terrés C; Ventayol P Gastroenterol Hepatol; 2013 Nov; 36(9):555-64. PubMed ID: 24119723 [TBL] [Abstract][Full Text] [Related]
9. The clinical effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people: a systematic review and economic evaluation. Hartwell D; Cooper K; Frampton GK; Baxter L; Loveman E Health Technol Assess; 2014 Oct; 18(65):i-xxii, 1-202. PubMed ID: 25350588 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security. Siebert U; Sroczynski G; ; Int J Technol Assess Health Care; 2005; 21(1):55-65. PubMed ID: 15736515 [TBL] [Abstract][Full Text] [Related]
11. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Shepherd J; Jones J; Hartwell D; Davidson P; Price A; Waugh N Health Technol Assess; 2007 Mar; 11(11):1-205, iii. PubMed ID: 17346498 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Sullivan SD; Jensen DM; Bernstein DE; Hassanein TI; Foster GR; Lee SS; Cheinquer H; Craxi A; Cooksley G; Klaskala W; Pettit K; Patel KK; Green J Am J Gastroenterol; 2004 Aug; 99(8):1490-6. PubMed ID: 15307866 [TBL] [Abstract][Full Text] [Related]
13. Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System. Yeh WS; Armstrong EP; Skrepnek GH; Malone DC Pharmacotherapy; 2007 Jun; 27(6):813-24. PubMed ID: 17542764 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients. Cure S; Bianic F; Gavart S; Curtis S; Lee S; Dusheiko G J Med Econ; 2014 Jan; 17(1):65-76. PubMed ID: 24160335 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients. Cure S; Bianic F; Gavart S; Curtis S; Lee S; Dusheiko G J Med Econ; 2014 Jan; 17(1):77-87. PubMed ID: 24032626 [TBL] [Abstract][Full Text] [Related]
16. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C. Carrión JA; Gonzalez-Colominas E; García-Retortillo M; Cañete N; Cirera I; Coll S; Giménez MD; Márquez C; Martin-Escudero V; Castellví P; Navinés R; Castaño JR; Galeras JA; Salas E; Bory F; Martín-Santos R; Solà R J Hepatol; 2013 Nov; 59(5):926-33. PubMed ID: 23811030 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden. Sennfält K; Reichard O; Hultkrantz R; Wong JB; Jonsson D Scand J Gastroenterol; 2001 Aug; 36(8):870-6. PubMed ID: 11495084 [TBL] [Abstract][Full Text] [Related]
18. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review. Shepherd J; Waugh N; Hewitson P Health Technol Assess; 2000; 4(33):1-67. PubMed ID: 11134916 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice. Grishchenko M; Grieve RD; Sweeting MJ; De Angelis D; Thomson BJ; Ryder SD; Irving WL; Int J Technol Assess Health Care; 2009 Apr; 25(2):171-80. PubMed ID: 19331708 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]